Health Catalyst Inc(HCAT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -3.68 | Insider Own | 18.19% | Shs Outstand | 74.6M | Perf Week | 2.37% |
| Market Cap | 0.13B | Forward P/E | 208.18 | EPS next Y | 118.03% | Insider Trans | - | Shs Float | 61.6M | Perf Month | -1.7% |
| Enterprise Value | 0.20B | PEG | - | EPS next Q | -0.05 | Inst Own | 61.4% | Short Float | 3.72% | Perf Quarter | 8.12% |
| Income | -0.26B | P/S | 0.45 | EPS this Y | -125.61% | Inst Trans | -7.66% | Short Ratio | 2.13 | Perf Half Y | -6.99% |
| Sales | 0.29B | P/B | 1.28 | EPS next 5Y | -21.32% | ROA | -54.33% | Short Interest | 2.29M | Perf YTD | -27.62% |
| Book/sh | 1.35 | P/C | 1.26 | EPS past 3/5Y | 1.04% 2.63% | ROE | -118.12% | 52W High | -52.14% ($3.62) | Perf Year | -46.93% |
| Cash/sh | 1.37 | P/FCF | 16.44 | Sales past 3/5Y | 4.05% 10.5% | ROIC | -99.75% | 52W Low | 81.13% ($0.96) | Perf 3Y | -85.16% |
| Dividend Est. | - | EV/EBITDA | 12.51 | EPS Y/Y TTM | -143.41% | Gross Margin | 34.54% | Volatility(W/M) | 5.94% 5.88% | Perf 5Y | -96.91% |
| Dividend TTM | - | EV/Sales | 0.67 | Sales Y/Y TTM | -7.54% | Oper. Margin | -11.25% | ATR (14) | 0.11 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.68 | EPS Q/Q | 6.88% | Profit Margin | -90.61% | RSI (14) | 47.84 | Recom | 2.67 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.68 | Sales Q/Q | -12.68% | SMA20 | 3.59% ($1.67) | Beta | 1.54 | Target Price | $1.82 |
| Payout | - | Debt/Eq | 1.69 | Earnings | 2026/8/6 | SMA50 | -11.26% ($1.95) | Rel Volume | 0.63 | Prev Close | $1.73 |
| Employees | 1200 | LT Debt/Eq | 1.63 | EPS/Sales Surpr. | 33.78% 2.02% | SMA200 | -6.65% ($1.85) | Avg Volume(3M) | 1.07M | Price | $1.73 |
| IPO | 2019/7/25 | Option/Short | Yes/Yes | Trades | 2696 | Volume | 677,092 | Change | - |
Company
HCAT is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
Health Catalyst is a US company that provides a data and analytics platform for hospitals and health systems. It integrates scattered clinical, financial, and operational data into a single analytics environment and supplies hospitals with software and professional services to help improve performance. Founded and headquartered in Utah, the company has expanded its presence in the hospital data analytics market since going public.
Over the past 1 year, roughly in the middle
52% below its 1-year high.
HCAT has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -125.6% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Would have changed by -85.2% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 61.4%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
SCDS 0.00%
VFVA 0.00%
IWC 0.00%
EES 0.00%
IWN 0.00%It ranks #4 in the industry
Based on market cap of $130M.
HCAT $130M PER -
VEEV $42B PER 42.9
BTSG $11B PER 43.2
TEM $11B PER -
FAQ
What kind of company is HCAT?
HCAT belongs to the Healthcare sector and operates in the Health Information Services industry.
What is the market cap of HCAT?
The market cap of HCAT is approximately $130M, ranking 4,403 within its sector.
What is the 52-week high and low for HCAT?
HCAT has recorded a 52-week high of $3.62 and a low of $0.96.
